.png)
This webinar focused on the potential of artificial intelligence (AI) in drug development, particularly within the realms of precision medicine. Hosted by Charlotte Guzzo, COO of Sano, the session featured insights from top industry experts who discussed their personal journeys at the intersection of technology and healthcare, the challenges of integrating AI into drug development, and the cutting-edge innovations their companies are pioneering.
Natural history studies play a pivotal role in deepening our understanding of diseases by observing them in their unmodified state. These studies offer invaluable insights by serving as "natural" comparisons for assessing the impact of treatments, thus playing a crucial role during the drug development process and in comprehending how diseases evolve without medical intervention. They act as fundamental benchmarks to gauge the effectiveness of new therapies.
In this webinar, Sano’s Senior Project Manager Clare Clarke shares the approach Sano employs to achieve its mission of accelerating the world’s transition to precision medicine. She outlines the seamless integration of recruitment, biomarker testing, and engagement within research trials, and provides an overview of Sano’s technology. This is the first in a series of webinars that will showcase various aspects of Sano’s product.
In recent years, the advent of population genomic screening has emerged as a promising approach to combat prevalent diseases such as cancer and heart disease. Population genetic screening tests a large population of otherwise healthy individuals to find genomic variants that might predispose them to diseases that are clinically actionable, meaning that they can be prevented or mitigated if they are detected early. By identifying individuals at risk of preventable and treatable conditions, this screening method has the potential to significantly reduce morbidity and mortality rates.
In this webinar, “Parkinson's disease: Engagement, screening, and retention," Sano CEO and Co-Founder Patrick Short shares a case study of Sano’s work on a genetic Parkinson’s disease clinical trial. He explores the methodologies used for this cutting-edge program, and describes the success of the project.
Our latest whitepaper, "Bridging Genes and Medicine: How genetics is redefining healthcare," examines how the adoption of genetic information is changing clinical practice by requiring a more personalised approach to healthcare. It highlights the importance of this shift, both for improving patient outcomes and for the efficiency of healthcare delivery, painting a picture of a future where treatments are as unique as the patients themselves.
Over the last two decades, following the landmark achievement of sequencing the first complete human genome, a suite of powerful genetic tools has emerged. Gene panel testing, whole exome sequencing, and whole genome sequencing are now pivotal in gathering detailed genetic information. The integration of these tools into neonatal care holds the potential for helpful genetic insight from the moment of birth.
Tissue engineering and regenerative medicine (TERM), integral to the evolution of precision medicine, are making strides in regenerating or repairing damaged tissues and organs. Tissue engineering uses cells, scaffolds, and growth factors to regenerate or replace damaged or diseased tissues, while regenerative medicine combines tissue engineering with other treatments like gene therapy, immunomodulation and cell-based therapy to induce tissue regeneration within the body. When combined with precision medicine's tailored approach, TERM holds immense promise for addressing some of the biggest modern healthcare issues, such as the urgent demand for organ replacements amidst an ageing population.
Last year, Sano CEO Dr. Patrick Short presented a webinar called “Genetics Essentials for Clinical Research professionals.” In it, he explained the fundamentals of genetics in clinical research, explored the trends propelling genetics in drug development, and shared practical applications in drug discovery, development, and delivery. Now, we’re back with part 2, which goes beyond fundamentals and is presented by Sano COO Charlotte Guzzo.
Genomic screening is transforming prenatal and neonatal care, offering new insights and challenges in equal measure. Our latest report, "Precision from the start: Balancing progress and principles in prenatal and neonatal care," dives into these advancements and the ethical dilemmas they present.